REG - GSK PLC - GSK announces positive DREAMM-7 headline results

GSKAnnouncement

27/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231127:nRSa6742Ua&default-theme=true

RNS Number : 6742U  GSK PLC  27 November 2023

Issued: 27 November 2023, London UK

 

GSK announces positive results from DREAMM-7 head-to-head phase III trial for
Blenrep in relapsed/refractory multiple myeloma

 

·   Blenrep (belantamab mafodotin) plus BorDex showed statistically
significant progression-free survival (PFS) benefit versus daratumumab plus
BorDex

·   Trial unblinded early based on Independent Data Monitoring Committee
(IDMC) recommendation

 

 

GSK plc (LSE/NYSE: GSK) today announced positive headline results from a
planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial
evaluating belantamab mafodotin as a second-line treatment for relapsed or
refractory multiple myeloma. The trial met its primary endpoint of
progression-free survival (PFS) and showed that belantamab mafodotin when
combined with bortezomib plus dexamethasone (BorDex) significantly extended
the time to disease progression or death versus daratumumab plus BorDex, an
existing standard of care for relapsed/refractory multiple myeloma. A strong
and clinically meaningful overall survival (OS) trend with nominal p value
< 0.0005 was also observed at the time of this analysis, and the trial
continues to follow up for OS.

 

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK,
said: "Patients with multiple myeloma need treatment options after first
relapse that are efficacious, readily accessible and have novel mechanisms of
action. We are particularly encouraged by the potential for belantamab
mafodotin when combined with BorDex to address high unmet need in
relapsed/refractory multiple myeloma, given the head-to-head comparison with
the daratumumab-based standard of care regimen."

 

The safety and tolerability of the belantamab mafodotin regimen was consistent
with the known safety profile of the individual agents.

 

Results from the interim analysis will be presented at an upcoming scientific
meeting and shared with health authorities.

 

The DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical
development programme continues to evaluate the potential of belantamab
mafodotin in early lines of treatment and in combination with novel therapies
and standard of care treatments. This includes the ongoing head-to-head phase
III DREAMM-8 trial evaluating belantamab mafodotin in combination with
pomalidomide and dexamethasone versus bortezomib in combination with
pomalidomide and dexamethasone. DREAMM-8 data are expected in the second half
of 2024.

 

About DREAMM-7

The DREAMM-7 phase III clinical trial is a multicentre, open-label, randomised
trial evaluating the efficacy and safety of belantamab mafodotin in
combination with bortezomib and dexamethasone (BorDex) compared to a
combination of daratumumab and BorDex in patients with relapsed/refractory
multiple myeloma who previously were treated with at least one prior line of
multiple myeloma therapy, with documented disease progression during or after
their most recent therapy.

 

A total of 494 participants were randomised at a 1:1 ratio to receive either
belantamab mafodotin in combination with BorDex or a combination of
daratumumab and BorDex. Participants had been previously treated with at least
one prior line of multiple myeloma therapy with documented disease progression
during or after their most recent therapy. Belantamab mafodotin was dosed at
2.5mg/kg intravenously every three weeks.

 

The primary endpoint is progression-free survival as per an independent review
committee. The key secondary endpoints include overall survival, duration of
response, and minimal residual disease negativity rate as assessed by
next-generation sequencing.

 

About multiple myeloma

Multiple myeloma is the third most common blood cancer globally and is
generally considered treatable but not curable.(1,2) There are approximately
176,000 new cases of multiple myeloma diagnosed globally each year.3 Research
into new therapies is needed as multiple myeloma commonly becomes refractory
to available treatments.(4)

 

About Blenrep

Blenrep is an antibody-drug conjugate comprising a humanised B-cell maturation
antigen monoclonal antibody conjugated to the cytotoxic agent auristatin F via
a non-cleavable linker. The drug linker technology is licensed from Seagen
Inc.; the monoclonal antibody is produced using POTELLIGENT Technology
licensed from BioWa Inc., a member of the Kyowa Kirin Group.

 

Refer to the Blenrep EMA Reference Information
(https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep) for a full list of
adverse events and the complete important safety information in the EU.

 

GSK in oncology

GSK is committed to maximising patient survival through transformational
medicines, with a current focus on breakthroughs in immuno-oncology and
tumour-cell targeting therapies, and development in haematologic malignancies,
gynaecologic cancers and other solid tumours.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Dan Smith          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022,
and Q3 Results for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

References

1 Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN
Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.

2 Kazandjian D. Multiple myeloma epidemiology and survival: A unique
malignancy. Semin Oncol. 2016;43(6):676-681.
doi:10.1053/j.seminoncol.2016.11.004.

3 Multiple Myeloma. World Health Organization International Agency for
Research on Cancer.
https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf.

4 Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed and
refractory multiple myeloma. Blood. 2015;125(20).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBBDBSDDDGXL